Skip to main content
Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

Fig 1.

Standard Timepoints For Study Collection, Screening Culture Eligibility based on Antibiotic Prescription and Discontinuation Dates.

(A) Based on Timepoint 0 as start point, we collected time elapsed from each subsequent date (Gram Stain Verbal Report, bacterial identification and antibiotic susceptibilities). (B) Cultures associated with ≥ 1 antibiotic prescription between date of bacterial identification and date of antibiotic susceptibilities were eligible for prescription analysis. As shown in B, culture had two associated antibiotics that met criteria (Antibiotic B and C). Only timeline for Antibiotic B would have been considered, since it had earliest start time. Subsequently, difference between start date for antibiotic B and date of blood culture collection will be calculated. (C) Cultures associated with ≥ 1 antibiotic prescription discontinued between “date of bacterial identification” and “72 hours post antibiotic susceptibility” were eligible for discontinuation time analysis. Here, antibiotics A and D would be ineligible, only antibiotic B and C met the criteria. We used earliest eligible antibiotic discontinued date (i.e., antibiotic B) and calculated difference between antibiotic B stop date with respect to date of blood culture collection.

More »

Fig 1 Expand

Table 1.

Frequencies of gram-negative pathogens among patient cultures (n = 377) and percentage of cultures per testing modality.

More »

Table 1 Expand

Table 2.

Mean times gram stain verbal reporting, bacterial identification and antibiotic susceptibilities*.

More »

Table 2 Expand

Table 3.

Time to empiric prescriptions and discontinuation of empiric therapy- MALDI vs. VITEK*.

More »

Table 3 Expand

Table 4.

Secondary analyses for empiric prescription and discontinuation times across MALDI vs. VITEK–enterobacteriaceae vs. Non-fermenters*; appropriateness of therapy changes.

More »

Table 4 Expand